JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $348,841,000 | -16.8% | 7,631,631 | -18.4% | 35.74% | -38.7% |
| Q3 2017 | $419,387,000 | -19.3% | 9,348,799 | -46.2% | 58.30% | -16.2% |
| Q2 2017 | $519,553,000 | +35.0% | 17,382,192 | +0.2% | 69.60% | -1.2% |
| Q1 2017 | $384,969,000 | +17.7% | 17,348,799 | 0.0% | 70.44% | -13.7% |
| Q4 2016 | $327,025,000 | -37.2% | 17,348,799 | 0.0% | 81.61% | +23.6% |
| Q3 2016 | $520,637,000 | -21.9% | 17,348,799 | 0.0% | 66.02% | -34.0% |
| Q2 2016 | $666,888,000 | +2.0% | 17,348,799 | 0.0% | 100.00% | 0.0% |
| Q1 2016 | $653,858,000 | -42.3% | 17,348,799 | -33.1% | 100.00% | 0.0% |
| Q4 2015 | $1,132,937,000 | +7.3% | 25,948,799 | 0.0% | 100.00% | 0.0% |
| Q3 2015 | $1,055,857,000 | -23.8% | 25,948,799 | -0.2% | 100.00% | 0.0% |
| Q2 2015 | $1,385,983,000 | -15.6% | 25,988,799 | -4.0% | 100.00% | 0.0% |
| Q1 2015 | $1,642,947,000 | +16.2% | 27,084,525 | 0.0% | 100.00% | 0.0% |
| Q4 2014 | $1,414,354,000 | – | 27,084,525 | – | 100.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |